Skip to main content
. Author manuscript; available in PMC: 2019 Mar 15.
Published in final edited form as: Radiol Clin North Am. 2015 Sep;53(5):933–971. doi: 10.1016/j.rcl.2015.05.012

Fig. 16.

Fig. 16.

(A) Enhanced CT shows a 1.2-cm CRLM in the right liver, near the dome (arrow). The mass is metabolically active on fused 18F-fluorodeoxyglucose (FDG) PET-CT (arrowhead). (B) Enhanced CT immediately following MW ablation. The 2.5-cm ablation encompasses the index lesion (arrowhead); however, it does not achieve the 1-cm margin needed to mitigate the risk of LTP. At surveillance enhanced CT and FDG PET-CT, there was LTP (arrows). (C) On unenhanced CT, 2 MW antennas are positioned within the index lesion with gas surrounding the antennas (arrowhead). Artificial ascites was infused before and during MW ablation. Enhanced CT immediately following MW ablation shows a 4.5-cm ablation (arrow) covering the prior ablation and a 10-mm margin.